| Medical and Health Sciences | 2021-2025 | 205 | US 77 | 99.96 |
| Obstetrics and Gynecology | Lifetime | 28 | US 7 | 99.79 |
| Reproductive Medicine | Lifetime | 38 | US 15 | 99.79 |
| Oncology | Lifetime | 397 | US 229 | 99.32 |
| Obstetrics and Gynecology | 2021-2025 | 6 | US 2 | 99.88 |
| Reproductive Medicine | 2021-2025 | 11 | US 2 | 99.74 |
| Oncology | 2021-2025 | 43 | US 16 | 99.76 |
| Epidemiology | 2021-2025 | 902 | US 326 | 90.92 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 844 | US 305 | 88.85 |
| Endometrial and Cervical Cancer Treatments | Lifetime | 9 | US 5 | 99.83 |
| Ovarian cancer diagnosis and treatment | Lifetime | 24 | US 14 | 99.77 |
| Colorectal and Anal Carcinomas | Lifetime | 25 | US 14 | 99.65 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 13 | US 6 | 99.56 |
| Cervical Cancer and HPV Research | Lifetime | 44 | US 21 | 99.67 |
| PARP inhibition in cancer therapy | Lifetime | 33 | US 18 | 99.36 |
| Cancer Mechanisms and Therapy | Lifetime | 51 | US 29 | 99.20 |
| Renal cell carcinoma treatment | Lifetime | 165 | US 98 | 99.09 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 448 | US 235 | 98.99 |
| Angiogenesis and VEGF in Cancer | Lifetime | 258 | US 122 | 98.34 |
| Sarcoma Diagnosis and Treatment | Lifetime | 451 | US 227 | 98.23 |
| Uterine Myomas and Treatments | Lifetime | 379 | US 130 | 97.50 |
| Cancer, Lipids, and Metabolism | Lifetime | 961 | US 442 | 96.70 |
| Economic and Financial Impacts of Cancer | Lifetime | 473 | US 304 | 95.31 |
| Management of metastatic bone disease | Lifetime | 439 | US 217 | 95.48 |
| Genital Health and Disease | Lifetime | 857 | US 370 | 93.54 |
| Intestinal and Peritoneal Adhesions | Lifetime | 560 | US 194 | 91.98 |
| Surgical Sutures and Adhesives | Lifetime | 548 | US 236 | 90.74 |
| Colorectal and Anal Carcinomas | 2021-2025 | 3 | US 1 | 99.66 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 5 | US 1 | 99.91 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 8 | US 2 | 99.87 |
| Cervical Cancer and HPV Research | 2021-2025 | 11 | US 3 | 99.55 |
| PARP inhibition in cancer therapy | 2021-2025 | 9 | US 4 | 99.68 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 125 | US 49 | 99.51 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 26 | US 6 | 94.05 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 546 | US 186 | 96.58 |
| BRCA gene mutations in cancer | 2021-2025 | 222 | US 105 | 93.08 |
| Cancer Mechanisms and Therapy | 2021-2025 | 132 | US 21 | 91.91 |
| HER2/EGFR in Cancer Research | 2021-2025 | 501 | US 183 | 91.77 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 586 | US 360 | 86.82 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 604 | US 147 | 78.16 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 912 | US 184 | 56.23 |
